Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19
Study sponsor: CytoDyn, Inc.
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2021-10-24Actual
Enrollment · participants484Actual
Source updated2025-10-15Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.